Characterization and inhibition of fibrin hydrogel-degrading enzymes during development of tissue engineering scaffolds

Tissue Engineering

Volumn 13, Issue 7, 2007, Pages 1469-1477

  Ahmed, Tamer A E ^a   Griffith, May ^a   Hincke, Max ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CARTILAGE; ENCAPSULATION; TISSUE ENGINEERING; TRANSCRIPTION FACTORS;

CHAIN REACTION; FIBRIN HYDROGEL-DEGRADING ENZYMES; FIBRIN HYDROGELS; METALLOPROTEINASES; TISSUE ENGINEERING SCAFFOLDS;

ENZYMES;

APROTININ; DNA; FIBRIN; GELATINASE A; GELATINASE B; ILOMASTAT; PLASMIN; PLASMINOGEN; RNA; SERINE PROTEINASE INHIBITOR; STROMELYSIN;

ANIMAL CELL; ARTICLE; CARTILAGINOUS TISSUE; CONTROLLED STUDY; ENCAPSULATION; ENZYME DEGRADATION; ENZYME REGULATION; ENZYME STABILITY; EXTRACELLULAR MATRIX; HYDROGEL; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TISSUE ENGINEERING; WESTERN BLOTTING; ZYMOGRAPHY;

ANIMALS; BIOCOMPATIBLE MATERIALS; CARTILAGE, ARTICULAR; CELL LINE; ENZYME INHIBITORS; ENZYMES; FIBRIN; HYDROGELS; RATS; TISSUE ENGINEERING;

EID: 34547120714     PISSN: 10763279     EISSN: None     Source Type: Journal    
DOI: 10.1089/ten.2006.0354     Document Type: Article

References (42)

1. Risbud, M.V., and Sittinger, M. Tissue engineering: advances in in-vitro cartilage generation (review). Trends Biotechnol. 20, 351, 2002.
2. Oshima, Y., Watanabe, N., Matsuda, K., Takai, S., Kawata, M., and Kubo, T. Fate of transplanted bone-marrow-derived mesenchymal cells during osteochondral repair using transgenic rats to stimulate autologous transplantation. Osteoarthr. Cartil. 12, 811, 2004.
3. Nehrer, S., Spector, M., and Minas, T. Histological analysis of tissue after failed cartilage repair procedures. Clin. Orthop. Relat. Res. 365, 149, 1999.
4. Jockenhoevel, S., Zund, G., Hoerstrup, S.P., Chalabi, K., Sachweh, J.S., Demircan, L., Messmer, B.J., and Turina, M. Fibrin gel - advantages of a new scaffold in cardiovascular tissue engineering. Eur. J. Cardiothorac. Surg. 19, 424, 2001.
5. Swartz, D.D., Russel, J.A., and Andreadis, S.T. Engineering of fibrin-based functional and implantable small-diameter blood vessels. Am. J. Physiol. Heart. Circ. Physiol. 288, H1451, 2005.
6. Fussenegger, M., Meinhart, J., Hobling, W., Kullich, W., Funk, S., and Bernatzky, G. Stabilized autologous fibrin-chondrocyte constructs for cartilage repair in vivo. Ann. Plast. Surg. 51, 493, 2003.
7. Muhs, B.E., Gagne, P., Plitas, G., Shaw, J.P., and Shamamian, P. Experimental hind limb ischemia leads to neutrophil-mediated increase in gastrocnemius MMP-2 and -9 activity, a potential mechanism for ischemia induced MMP activation. J. Surg. Res. 117, 249, 2004.
8. Cawston, T.E. Metalloproteinase inhibitors and the prevention of connective tissue breakdown (review). Pharmacol. Ther. 70, 163, 1996.
9. Massova, I., Kotra, L.P., Fridman, R., and Mobashery, S. Matrix metalloproteinase: structures, evolution, and diversification. FASEB J. 12, 1075, 1998.
10. Gingras, D., Page, M., Annabi, I.B., and Beliveau, R. Rapid activation of matrix metalloproteinase-2 by glioma cells occurs through a post-translational MT1-MMP-dependent mechanism. Biochem. Biophys. Acta. 1497, 341, 2000.
11. Majka, S., McGuire, P., Colombo, S., and Das, A. The balance between proteinases and inhibitors in a murine model of proliferative retinopathy. Invest. Ophthalmol. Vis. Sci. 42, 210, 2001.
12. Gijbels, K., Galardy, R.E., and Steinman, L. Reversal of experimental autoimmune encephalomyelitis with a hydroxamate inhibitor of matrix metalloproteinases. J. Clin. Invest. 94, 2177, 1994.
13. Hao, J.L., Nagano, T., Nakamura, M., Kumagai, N., Mishima, H., and Nishida, T. Galardin inhibits collagen degradation by rabbit keratocytes by inhibiting the activation of pro-matrix metalloproteinases. Exp. Eye Res. 68, 565, 1999.
14. Collen, D. Ham-Wasserman lecture: role of the plasminogen system in fibrin-homeostasis and tissue remodeling (Review). Hematology Am. Soc. Hematol. Educ. Program 1, 2001.
15. Morgan, H., and Hill, P.A. Human breast cancer cell-mediated bone collagen degradation requires plasminogen activation and matrix metalloproteinase activity. Cancer Cell Int. 5, 1, 2005.
16. Kang, H.M., Kalnoski, M.H., Frederick, M., and Chandler, W.L. The kinetics of plasmin inhibition by aprotinin in vivo. Thromb. Res. 115, 327, 2005.
17. Grigoriadis, A.E., Heersche, J.N., and Aubin, J.E. Analysis of chondroprogenitor frequency and cartilage differentiation in a novel family of clonal chondrogenic rat cell lines. Differentiation 60, 299, 1996.
18. Waas, E.T., Lomme. R.M, DeGroot, J., Wobbes, T., and Hendriks, T. Tissue levels of active matrix metalloproteinase-2 and -9 in colorectal cancer. Br. J. Cancer 86, 1876, 2002.
19. Lantz, M.S., and Ciborowski, P. Zymographic techniques for detection and characterization of microbial protease. Meth. Enzymol. 235, 563, 1994.
20. Laemmli, U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227, 680, 1970.
21. Towbin, H., Staehelen, T., and Gordon, J. Electophoretic transfer of protein from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc. Natl. Acad. Sci. U. S. A.76, 4350, 1979.
22. Byun, Y., and Yang, V.C. Delivery system for targeted thrombolysis without the risk of hemorrhage. ASAIO J. 44, M638, 1998.
23. Han, B., Schwab, I.R., Madsen, T.K., and Isseroff, R.R. A fibrin- based bioengineered ocular surface with human corneal epithelial stem cells. Cornea 21, 505, 2002.
24. Meinhart, J., Fussenegger, M., and Hobling, W. Stabilization of fibrin-chondrocyte constructs for cartilage reconstruction. Ann. Plast. Surg. 42, 673, 1999.
25. Sabatini, M., Lesur, C., Thomas, M., Chomel, A., Anract, P., de Nanteuil, G., and Pastoureau, P. Effect of inhibition of matrix metalloproteinases on cartilage loss in vitro and in guinea pig model of osteoarthritis. Arthritis Rheum. 52, 171, 2005.
26. Yamada, H., Stephens, R.W., Nakagawa, T. and McNicol, D. Detection and partial characterization of a specific plasminogen activator inhibitor in human chondrocyte culture. J. Biochem. (Tokyo) 104, 960, 1988.
27. Twining, S.S., Wilson, P.M., and Ngamkitidechakul, C. Extrahepatic synthesis of plasminogen in the human cornea is up-regulated by interleukins-1 alpha and -1beta. Biochem. J. 339, 705, 1999.
28. Kasza, A., Kiss, D.L., Gopalan, S., Xu, W., Rydel, R.E., Koj, A., and Kordula, T. Mechanism of plasminogen activator inhibitor-1 regulation by oncostatin M and interleukin-1 in human astrocytes. J. Neurochem. 83, 696, 2002.
29. Cai, G., Chen, X., Fu, B., and Lu, Y. Activation of gelatinases by fibrin is a PA/plasmin system-dependent in human glomerular endothelial cells. Mol. Cell. Biochem. 277, 171, 2005.
30. Oliver, J.J., Webb, D., and Newby, D.E. Stimulated tissue plasminogen activator release as a marker of endothelial functions in humans. Arterioscler. Thromb. Vasc. Biol. 25, 2470, 2005.
31. Dean, D.D., Martel-Pelletier, J., Pelletier, J.P., Howell, D.S., and Woessner, J.F. Evidence for metalloproteinase and metalloproteinase inhibitor imbalance in human osteoarthritic cartilage. J. Clin. Invest. 84, 678, 1989.
32. Martel-Pelletier, J., Zafarullah, M., Kodama, S., and Pelletier, J. P. In vitro effects of interleukin 1 on the synthesis of metalloproteinases, TIMP, plasminogen activators and inhibitors in human articular cartilage. J. Rheumatol. Suppl. 27, 80, 1991.
33. Urech, L., Bittermann, A.G., Hubbell, J.A., and Hall, Heike. Mechanical properties, proteolytic degradability and biological modifications affect angiogenic process extension into native and modified fibrin matrices in vitro. Biomaterials 26, 1369, 2005.
34. Hiraoka, N., Allen, E., Apel, I.J., Gyetko, M.R., and Weiss, S.J. Matrix metalloproteinases regulate neovascularization by acting as pericellular fibrinolysins. Cell 95, 365, 1998.
35. Hiller, O., Lichte, A., Oberpichler, A., Kocourek, A., and Tschesche, H. Matrix metalloproteinases collagenase-3, and membrane type 1- matrix metalloproteinase impair clotting by degradation of fibrinogen and factor XII. J. Biol. Chem. 275, 33008, 2000.
36. Eyrich, D., Brandl, F., Appel, B., Wiese, H., Maier, G., Wenzel, M., Staudenmaier, R., Goepferich, A., and Blunk, T. Long-term stable fibrin gels for cartilage engineering. Biomaterials 28, 55, 2007.
37. Dikovsky, D., Bianco-Peled, H., and Seliktar, D. The effect of structural alterations of PEG-fibrinogen hydrogel scaffolds on 3-D cellular morphology and cellular migration. Biomaterials 27, 1496, 2006.
38. Kassis, I., Zangi, L., Levdansky, L., Samuel, S., Marx, G., and Gorodetsky, R. Isolation of mesenchymal stem cells form G-CSF-mobilized human peripheral blood using fibrin microbeads. Bone Marrow Transplant. 37, 967, 2006.
39. Passaretti, D., Silvermn, R.P., Huang, W., Kirchhoff, C.H., Ashiku, S., Randolph, M.A., and Yaremchuk, M.J. Cultured chondrocytes produce injectable tissue-engineered cartilage in hydrogel polymer. Tissue Eng. 7, 805, 2001
40. Ramont, L., Pasco, S., Hornebeck, W., Maquart, F.X., and Monboisse, J.C. Transforming growth factor β1 inhibits tumor growth in a mouse melanoma model by down-regulating the plasminogen activation system. Exp. Cell. Res. 291, 1, 2003.
41. Ratel, D., Glazier, G., Provencal, M., Boivin, D., Beaulieu, E., Gingras, D., and Beliveau, R. Direct-acting fibrinolytic enzymes in shark cartilage extract: potential therapeutic role in vascular disorders. Thromb. Res. 115, 143, 2005.
42. Baricos, W.H., Cortez, S.L., El-Dahr, S.S., and Schnaper, H.W. ECM degradation by cultured human mesangial cells is mediated by a PA/plasmin/MMP-2 cascade. Kidney Int. 47, 1039, 1995.